PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
- PMID: 37833089
- PMCID: PMC10575658
- DOI: 10.46747/cfp.6910675
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
Abstract
Objective: To update the 2015 clinical practice guideline and provide a simplified approach to lipid management in the prevention of cardiovascular disease (CVD) for primary care.
Methods: Following the Institute of Medicine's Clinical Practice Guidelines We Can Trust, a multidisciplinary, pan-Canadian guideline panel was formed. This panel was represented by primary care providers, free from conflicts of interest with industry, and included the patient perspective. A separate scientific evidence team performed evidence reviews on statins, ezetimibe, proprotein convertase subtilisin-kexin type 9 inhibitors, fibrates, bile acid sequestrants, niacin, and omega-3 supplements (docosahexaenoic acid with eicosapentaenoic acid [EPA] or EPA ethyl ester alone [icosapent]), as well as on 11 supplemental questions. Recommendations were finalized by the guideline panel through use of the Grading of Recommendations Assessment, Development and Evaluation methodology.
Recommendations: All recommendations are presented in a patient-centred manner designed with the needs of family physicians and other primary care providers in mind. Many recommendations are similar to those published in 2015. Statins remain first-line therapy for both primary and secondary CVD prevention, and the Mediterranean diet and physical activity are recommended to reduce cardiovascular risk (primary and secondary prevention). The guideline panel recommended against using lipoprotein a, apolipoprotein B, or coronary artery calcium levels when assessing cardiovascular risk, and recommended against targeting specific lipid levels. The team also reviewed new evidence pertaining to omega-3 fatty acids (including EPA ethyl ester [icosapent]) and proprotein convertase subtilisin-kexin type 9 inhibitors, and outlined when to engage in informed shared decision making with patients on interventions to lower cardiovascular risk.
Conclusion: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.
Copyright © 2023 the College of Family Physicians of Canada.
Figures
Comment in
-
Response.Can Fam Physician. 2024 Jun;70(6):371. doi: 10.46747/cfp.7006371_1. Can Fam Physician. 2024. PMID: 38886080 Free PMC article. No abstract available.
-
Repeat lipid testing.Can Fam Physician. 2024 Jun;70(6):371. doi: 10.46747/cfp.7006371. Can Fam Physician. 2024. PMID: 38886085 Free PMC article. No abstract available.
References
-
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139(25):e1046-81. Erratum in: Circulation 2019;139(25):e1178-81. - PubMed
-
- Authors/task force members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. Epub 2019 Aug 31. Errata in: Atherosclerosis 2020;292:160-2, Atherosclerosis 2020;294:80-2. - PubMed
-
- O’Malley PG, Arnold MJ, Kelley C, Spacek L, Buelt A, Natarajan S, et al. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med 2020;173(10):822-9. Epub 2020 Sep 22. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials